1. Home
  2. XOMA vs AGEN Comparison

XOMA vs AGEN Comparison

Compare XOMA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMA
  • AGEN
  • Stock Information
  • Founded
  • XOMA N/A
  • AGEN 1994
  • Country
  • XOMA United States
  • AGEN United States
  • Employees
  • XOMA N/A
  • AGEN N/A
  • Industry
  • XOMA Biotechnology: Pharmaceutical Preparations
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XOMA Health Care
  • AGEN Health Care
  • Exchange
  • XOMA Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • XOMA 298.3M
  • AGEN 286.0M
  • IPO Year
  • XOMA N/A
  • AGEN 2000
  • Fundamental
  • Price
  • XOMA $27.00
  • AGEN $15.60
  • Analyst Decision
  • XOMA Strong Buy
  • AGEN Strong Buy
  • Analyst Count
  • XOMA 2
  • AGEN 2
  • Target Price
  • XOMA $57.00
  • AGEN $70.00
  • AVG Volume (30 Days)
  • XOMA 31.6K
  • AGEN 552.0K
  • Earning Date
  • XOMA 08-06-2024
  • AGEN 08-06-2024
  • Dividend Yield
  • XOMA N/A
  • AGEN N/A
  • EPS Growth
  • XOMA N/A
  • AGEN N/A
  • EPS
  • XOMA N/A
  • AGEN N/A
  • Revenue
  • XOMA $5,811,000.00
  • AGEN $161,416,000.00
  • Revenue This Year
  • XOMA $349.94
  • AGEN $43.78
  • Revenue Next Year
  • XOMA $28.50
  • AGEN N/A
  • P/E Ratio
  • XOMA N/A
  • AGEN N/A
  • Revenue Growth
  • XOMA 73.10
  • AGEN 69.94
  • 52 Week Low
  • XOMA $13.48
  • AGEN $4.78
  • 52 Week High
  • XOMA $27.36
  • AGEN $37.40
  • Technical
  • Relative Strength Index (RSI)
  • XOMA 58.66
  • AGEN 54.16
  • Support Level
  • XOMA $24.36
  • AGEN $15.05
  • Resistance Level
  • XOMA $27.10
  • AGEN $16.12
  • Average True Range (ATR)
  • XOMA 1.39
  • AGEN 1.18
  • MACD
  • XOMA 0.27
  • AGEN -0.05
  • Stochastic Oscillator
  • XOMA 98.09
  • AGEN 43.63

About XOMA XOMA Corporation

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: